カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の腺筋症治療薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Adenomyosis Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19101）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19101
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：110
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の腺筋症治療薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

腺筋症治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の腺筋症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

腺筋症治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・ホルモン剤、抗炎症剤、その他

用途別セグメントは次のように区分されます。
・病院、診療所、薬局、その他

世界の腺筋症治療薬市場の主要な市場プレーヤーは以下のとおりです。
・Accord Healthcare、Tolmar Pharmaceuticals、Mayne Pharma Group、Hikma Pharmaceuticals PLC、Boehringer Ingelheim International GmbH、TerSera Therapeutics、Ferring Pharmaceuticals、Lannett、Endo International、Context Therapeutics、Viatris、Bayer AG、Teva Pharmaceutical Industries、AstraZeneca、Sanofi、Merck、Novartis、Pfizer

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、腺筋症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な腺筋症治療薬メーカーの企業概要、2019年～2022年までの腺筋症治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な腺筋症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別腺筋症治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの腺筋症治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での腺筋症治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および腺筋症治療薬の産業チェーンを掲載しています。
・第13、14、15章では、腺筋症治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 腺筋症治療薬の概要
- 種類別分析（2017年vs2021年vs2028年）：ホルモン剤、抗炎症剤、その他
- 用途別分析（2017年vs2021年vs2028年）：病院、診療所、薬局、その他
- 世界の腺筋症治療薬市場規模・予測
- 世界の腺筋症治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Accord Healthcare、Tolmar Pharmaceuticals、Mayne Pharma Group、Hikma Pharmaceuticals PLC、Boehringer Ingelheim International GmbH、TerSera Therapeutics、Ferring Pharmaceuticals、Lannett、Endo International、Context Therapeutics、Viatris、Bayer AG、Teva Pharmaceutical Industries、AstraZeneca、Sanofi、Merck、Novartis、Pfizer
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ホルモン剤、抗炎症剤、その他
・用途別分析2017年-2028年：病院、診療所、薬局、その他
・腺筋症治療薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・腺筋症治療薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・腺筋症治療薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・腺筋症治療薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・腺筋症治療薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Adenomyosis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Adenomyosis Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospitals accounting for % of the Adenomyosis Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Hormone Medications segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Adenomyosis Drugs include Accord Healthcare, Tolmar Pharmaceuticals, Mayne Pharma Group, Hikma Pharmaceuticals PLC, and Boehringer Ingelheim International GmbH, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Adenomyosis Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Hormone Medications
Anti-inflammatory Drugs
Others
Market segment by Application can be divided into
Hospitals
Clinics
Pharmacy
Others
The key market players for global Adenomyosis Drugs market are listed below:
Accord Healthcare
Tolmar Pharmaceuticals
Mayne Pharma Group
Hikma Pharmaceuticals PLC
Boehringer Ingelheim International GmbH
TerSera Therapeutics
Ferring Pharmaceuticals
Lannett
Endo International
Context Therapeutics
Viatris
Bayer AG
Teva Pharmaceutical Industries
AstraZeneca
Sanofi
Merck
Novartis
Pfizer
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adenomyosis Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Adenomyosis Drugs, with price, sales, revenue and global market share of Adenomyosis Drugs from 2019 to 2022.
Chapter 3, the Adenomyosis Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adenomyosis Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Adenomyosis Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Adenomyosis Drugs.
Chapter 13, 14, and 15, to describe Adenomyosis Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Adenomyosis Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Adenomyosis Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Hormone Medications
1.2.3 Anti-inflammatory Drugs
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Adenomyosis Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Pharmacy
1.3.5 Others
1.4 Global Adenomyosis Drugs Market Size & Forecast
1.4.1 Global Adenomyosis Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Adenomyosis Drugs Sales in Volume (2017-2028)
1.4.3 Global Adenomyosis Drugs Price (2017-2028)
1.5 Global Adenomyosis Drugs Production Capacity Analysis
1.5.1 Global Adenomyosis Drugs Total Production Capacity (2017-2028)
1.5.2 Global Adenomyosis Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Adenomyosis Drugs Market Drivers
1.6.2 Adenomyosis Drugs Market Restraints
1.6.3 Adenomyosis Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Accord Healthcare
2.1.1 Accord Healthcare Details
2.1.2 Accord Healthcare Major Business
2.1.3 Accord Healthcare Adenomyosis Drugs Product and Services
2.1.4 Accord Healthcare Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Tolmar Pharmaceuticals
2.2.1 Tolmar Pharmaceuticals Details
2.2.2 Tolmar Pharmaceuticals Major Business
2.2.3 Tolmar Pharmaceuticals Adenomyosis Drugs Product and Services
2.2.4 Tolmar Pharmaceuticals Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Mayne Pharma Group
2.3.1 Mayne Pharma Group Details
2.3.2 Mayne Pharma Group Major Business
2.3.3 Mayne Pharma Group Adenomyosis Drugs Product and Services
2.3.4 Mayne Pharma Group Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Hikma Pharmaceuticals PLC
2.4.1 Hikma Pharmaceuticals PLC Details
2.4.2 Hikma Pharmaceuticals PLC Major Business
2.4.3 Hikma Pharmaceuticals PLC Adenomyosis Drugs Product and Services
2.4.4 Hikma Pharmaceuticals PLC Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Boehringer Ingelheim International GmbH
2.5.1 Boehringer Ingelheim International GmbH Details
2.5.2 Boehringer Ingelheim International GmbH Major Business
2.5.3 Boehringer Ingelheim International GmbH Adenomyosis Drugs Product and Services
2.5.4 Boehringer Ingelheim International GmbH Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 TerSera Therapeutics
2.6.1 TerSera Therapeutics Details
2.6.2 TerSera Therapeutics Major Business
2.6.3 TerSera Therapeutics Adenomyosis Drugs Product and Services
2.6.4 TerSera Therapeutics Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Ferring Pharmaceuticals
2.7.1 Ferring Pharmaceuticals Details
2.7.2 Ferring Pharmaceuticals Major Business
2.7.3 Ferring Pharmaceuticals Adenomyosis Drugs Product and Services
2.7.4 Ferring Pharmaceuticals Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Lannett
2.8.1 Lannett Details
2.8.2 Lannett Major Business
2.8.3 Lannett Adenomyosis Drugs Product and Services
2.8.4 Lannett Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Endo International
2.9.1 Endo International Details
2.9.2 Endo International Major Business
2.9.3 Endo International Adenomyosis Drugs Product and Services
2.9.4 Endo International Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Context Therapeutics
2.10.1 Context Therapeutics Details
2.10.2 Context Therapeutics Major Business
2.10.3 Context Therapeutics Adenomyosis Drugs Product and Services
2.10.4 Context Therapeutics Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Viatris
2.11.1 Viatris Details
2.11.2 Viatris Major Business
2.11.3 Viatris Adenomyosis Drugs Product and Services
2.11.4 Viatris Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Bayer AG
2.12.1 Bayer AG Details
2.12.2 Bayer AG Major Business
2.12.3 Bayer AG Adenomyosis Drugs Product and Services
2.12.4 Bayer AG Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Teva Pharmaceutical Industries
2.13.1 Teva Pharmaceutical Industries Details
2.13.2 Teva Pharmaceutical Industries Major Business
2.13.3 Teva Pharmaceutical Industries Adenomyosis Drugs Product and Services
2.13.4 Teva Pharmaceutical Industries Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 AstraZeneca
2.14.1 AstraZeneca Details
2.14.2 AstraZeneca Major Business
2.14.3 AstraZeneca Adenomyosis Drugs Product and Services
2.14.4 AstraZeneca Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Sanofi
2.15.1 Sanofi Details
2.15.2 Sanofi Major Business
2.15.3 Sanofi Adenomyosis Drugs Product and Services
2.15.4 Sanofi Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Merck
2.16.1 Merck Details
2.16.2 Merck Major Business
2.16.3 Merck Adenomyosis Drugs Product and Services
2.16.4 Merck Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 Novartis
2.17.1 Novartis Details
2.17.2 Novartis Major Business
2.17.3 Novartis Adenomyosis Drugs Product and Services
2.17.4 Novartis Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Pfizer
2.18.1 Pfizer Details
2.18.2 Pfizer Major Business
2.18.3 Pfizer Adenomyosis Drugs Product and Services
2.18.4 Pfizer Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Adenomyosis Drugs Breakdown Data by Manufacturer
3.1 Global Adenomyosis Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Adenomyosis Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Adenomyosis Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Adenomyosis Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Adenomyosis Drugs Manufacturer Market Share in 2021
3.5 Global Adenomyosis Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Adenomyosis Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Adenomyosis Drugs Market Size by Region
4.1.1 Global Adenomyosis Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Adenomyosis Drugs Revenue by Region (2017-2028)
4.2 North America Adenomyosis Drugs Revenue (2017-2028)
4.3 Europe Adenomyosis Drugs Revenue (2017-2028)
4.4 Asia-Pacific Adenomyosis Drugs Revenue (2017-2028)
4.5 South America Adenomyosis Drugs Revenue (2017-2028)
4.6 Middle East and Africa Adenomyosis Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Adenomyosis Drugs Sales in Volume by Type (2017-2028)
5.2 Global Adenomyosis Drugs Revenue by Type (2017-2028)
5.3 Global Adenomyosis Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Adenomyosis Drugs Sales in Volume by Application (2017-2028)
6.2 Global Adenomyosis Drugs Revenue by Application (2017-2028)
6.3 Global Adenomyosis Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Adenomyosis Drugs Sales by Type (2017-2028)
7.2 North America Adenomyosis Drugs Sales by Application (2017-2028)
7.3 North America Adenomyosis Drugs Market Size by Country
7.3.1 North America Adenomyosis Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Adenomyosis Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Adenomyosis Drugs Sales by Type (2017-2028)
8.2 Europe Adenomyosis Drugs Sales by Application (2017-2028)
8.3 Europe Adenomyosis Drugs Market Size by Country
8.3.1 Europe Adenomyosis Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Adenomyosis Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Adenomyosis Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Adenomyosis Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Adenomyosis Drugs Market Size by Region
9.3.1 Asia-Pacific Adenomyosis Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Adenomyosis Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Adenomyosis Drugs Sales by Type (2017-2028)
10.2 South America Adenomyosis Drugs Sales by Application (2017-2028)
10.3 South America Adenomyosis Drugs Market Size by Country
10.3.1 South America Adenomyosis Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Adenomyosis Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Adenomyosis Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Adenomyosis Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Adenomyosis Drugs Market Size by Country
11.3.1 Middle East & Africa Adenomyosis Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Adenomyosis Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Adenomyosis Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Adenomyosis Drugs
12.3 Adenomyosis Drugs Production Process
12.4 Adenomyosis Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Adenomyosis Drugs Typical Distributors
13.3 Adenomyosis Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Adenomyosis Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Adenomyosis Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Accord Healthcare Basic Information, Manufacturing Base and Competitors
Table 4. Accord Healthcare Major Business
Table 5. Accord Healthcare Adenomyosis Drugs Product and Services
Table 6. Accord Healthcare Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Tolmar Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 8. Tolmar Pharmaceuticals Major Business
Table 9. Tolmar Pharmaceuticals Adenomyosis Drugs Product and Services
Table 10. Tolmar Pharmaceuticals Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Mayne Pharma Group Basic Information, Manufacturing Base and Competitors
Table 12. Mayne Pharma Group Major Business
Table 13. Mayne Pharma Group Adenomyosis Drugs Product and Services
Table 14. Mayne Pharma Group Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Hikma Pharmaceuticals PLC Basic Information, Manufacturing Base and Competitors
Table 16. Hikma Pharmaceuticals PLC Major Business
Table 17. Hikma Pharmaceuticals PLC Adenomyosis Drugs Product and Services
Table 18. Hikma Pharmaceuticals PLC Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Boehringer Ingelheim International GmbH Basic Information, Manufacturing Base and Competitors
Table 20. Boehringer Ingelheim International GmbH Major Business
Table 21. Boehringer Ingelheim International GmbH Adenomyosis Drugs Product and Services
Table 22. Boehringer Ingelheim International GmbH Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. TerSera Therapeutics Basic Information, Manufacturing Base and Competitors
Table 24. TerSera Therapeutics Major Business
Table 25. TerSera Therapeutics Adenomyosis Drugs Product and Services
Table 26. TerSera Therapeutics Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Ferring Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 28. Ferring Pharmaceuticals Major Business
Table 29. Ferring Pharmaceuticals Adenomyosis Drugs Product and Services
Table 30. Ferring Pharmaceuticals Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Lannett Basic Information, Manufacturing Base and Competitors
Table 32. Lannett Major Business
Table 33. Lannett Adenomyosis Drugs Product and Services
Table 34. Lannett Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Endo International Basic Information, Manufacturing Base and Competitors
Table 36. Endo International Major Business
Table 37. Endo International Adenomyosis Drugs Product and Services
Table 38. Endo International Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Context Therapeutics Basic Information, Manufacturing Base and Competitors
Table 40. Context Therapeutics Major Business
Table 41. Context Therapeutics Adenomyosis Drugs Product and Services
Table 42. Context Therapeutics Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Viatris Basic Information, Manufacturing Base and Competitors
Table 44. Viatris Major Business
Table 45. Viatris Adenomyosis Drugs Product and Services
Table 46. Viatris Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 48. Bayer AG Major Business
Table 49. Bayer AG Adenomyosis Drugs Product and Services
Table 50. Bayer AG Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 52. Teva Pharmaceutical Industries Major Business
Table 53. Teva Pharmaceutical Industries Adenomyosis Drugs Product and Services
Table 54. Teva Pharmaceutical Industries Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 56. AstraZeneca Major Business
Table 57. AstraZeneca Adenomyosis Drugs Product and Services
Table 58. AstraZeneca Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Sanofi Basic Information, Manufacturing Base and Competitors
Table 60. Sanofi Major Business
Table 61. Sanofi Adenomyosis Drugs Product and Services
Table 62. Sanofi Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 63. Merck Basic Information, Manufacturing Base and Competitors
Table 64. Merck Major Business
Table 65. Merck Adenomyosis Drugs Product and Services
Table 66. Merck Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 67. Novartis Basic Information, Manufacturing Base and Competitors
Table 68. Novartis Major Business
Table 69. Novartis Adenomyosis Drugs Product and Services
Table 70. Novartis Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 71. Pfizer Basic Information, Manufacturing Base and Competitors
Table 72. Pfizer Major Business
Table 73. Pfizer Adenomyosis Drugs Product and Services
Table 74. Pfizer Adenomyosis Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 75. Global Adenomyosis Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 76. Global Adenomyosis Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 77. Market Position of Manufacturers in Adenomyosis Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 78. Global Adenomyosis Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 79. Head Office and Adenomyosis Drugs Production Site of Key Manufacturer
Table 80. Adenomyosis Drugs New Entrant and Capacity Expansion Plans
Table 81. Adenomyosis Drugs Mergers & Acquisitions in the Past Five Years
Table 82. Global Adenomyosis Drugs Sales by Region (2017-2022) & (K Units)
Table 83. Global Adenomyosis Drugs Sales by Region (2023-2028) & (K Units)
Table 84. Global Adenomyosis Drugs Revenue by Region (2017-2022) & (USD Million)
Table 85. Global Adenomyosis Drugs Revenue by Region (2023-2028) & (USD Million)
Table 86. Global Adenomyosis Drugs Sales by Type (2017-2022) & (K Units)
Table 87. Global Adenomyosis Drugs Sales by Type (2023-2028) & (K Units)
Table 88. Global Adenomyosis Drugs Revenue by Type (2017-2022) & (USD Million)
Table 89. Global Adenomyosis Drugs Revenue by Type (2023-2028) & (USD Million)
Table 90. Global Adenomyosis Drugs Price by Type (2017-2022) & (US$/Unit)
Table 91. Global Adenomyosis Drugs Price by Type (2023-2028) & (US$/Unit)
Table 92. Global Adenomyosis Drugs Sales by Application (2017-2022) & (K Units)
Table 93. Global Adenomyosis Drugs Sales by Application (2023-2028) & (K Units)
Table 94. Global Adenomyosis Drugs Revenue by Application (2017-2022) & (USD Million)
Table 95. Global Adenomyosis Drugs Revenue by Application (2023-2028) & (USD Million)
Table 96. Global Adenomyosis Drugs Price by Application (2017-2022) & (US$/Unit)
Table 97. Global Adenomyosis Drugs Price by Application (2023-2028) & (US$/Unit)
Table 98. North America Adenomyosis Drugs Sales by Country (2017-2022) & (K Units)
Table 99. North America Adenomyosis Drugs Sales by Country (2023-2028) & (K Units)
Table 100. North America Adenomyosis Drugs Revenue by Country (2017-2022) & (USD Million)
Table 101. North America Adenomyosis Drugs Revenue by Country (2023-2028) & (USD Million)
Table 102. North America Adenomyosis Drugs Sales by Type (2017-2022) & (K Units)
Table 103. North America Adenomyosis Drugs Sales by Type (2023-2028) & (K Units)
Table 104. North America Adenomyosis Drugs Sales by Application (2017-2022) & (K Units)
Table 105. North America Adenomyosis Drugs Sales by Application (2023-2028) & (K Units)
Table 106. Europe Adenomyosis Drugs Sales by Country (2017-2022) & (K Units)
Table 107. Europe Adenomyosis Drugs Sales by Country (2023-2028) & (K Units)
Table 108. Europe Adenomyosis Drugs Revenue by Country (2017-2022) & (USD Million)
Table 109. Europe Adenomyosis Drugs Revenue by Country (2023-2028) & (USD Million)
Table 110. Europe Adenomyosis Drugs Sales by Type (2017-2022) & (K Units)
Table 111. Europe Adenomyosis Drugs Sales by Type (2023-2028) & (K Units)
Table 112. Europe Adenomyosis Drugs Sales by Application (2017-2022) & (K Units)
Table 113. Europe Adenomyosis Drugs Sales by Application (2023-2028) & (K Units)
Table 114. Asia-Pacific Adenomyosis Drugs Sales by Region (2017-2022) & (K Units)
Table 115. Asia-Pacific Adenomyosis Drugs Sales by Region (2023-2028) & (K Units)
Table 116. Asia-Pacific Adenomyosis Drugs Revenue by Region (2017-2022) & (USD Million)
Table 117. Asia-Pacific Adenomyosis Drugs Revenue by Region (2023-2028) & (USD Million)
Table 118. Asia-Pacific Adenomyosis Drugs Sales by Type (2017-2022) & (K Units)
Table 119. Asia-Pacific Adenomyosis Drugs Sales by Type (2023-2028) & (K Units)
Table 120. Asia-Pacific Adenomyosis Drugs Sales by Application (2017-2022) & (K Units)
Table 121. Asia-Pacific Adenomyosis Drugs Sales by Application (2023-2028) & (K Units)
Table 122. South America Adenomyosis Drugs Sales by Country (2017-2022) & (K Units)
Table 123. South America Adenomyosis Drugs Sales by Country (2023-2028) & (K Units)
Table 124. South America Adenomyosis Drugs Revenue by Country (2017-2022) & (USD Million)
Table 125. South America Adenomyosis Drugs Revenue by Country (2023-2028) & (USD Million)
Table 126. South America Adenomyosis Drugs Sales by Type (2017-2022) & (K Units)
Table 127. South America Adenomyosis Drugs Sales by Type (2023-2028) & (K Units)
Table 128. South America Adenomyosis Drugs Sales by Application (2017-2022) & (K Units)
Table 129. South America Adenomyosis Drugs Sales by Application (2023-2028) & (K Units)
Table 130. Middle East & Africa Adenomyosis Drugs Sales by Region (2017-2022) & (K Units)
Table 131. Middle East & Africa Adenomyosis Drugs Sales by Region (2023-2028) & (K Units)
Table 132. Middle East & Africa Adenomyosis Drugs Revenue by Region (2017-2022) & (USD Million)
Table 133. Middle East & Africa Adenomyosis Drugs Revenue by Region (2023-2028) & (USD Million)
Table 134. Middle East & Africa Adenomyosis Drugs Sales by Type (2017-2022) & (K Units)
Table 135. Middle East & Africa Adenomyosis Drugs Sales by Type (2023-2028) & (K Units)
Table 136. Middle East & Africa Adenomyosis Drugs Sales by Application (2017-2022) & (K Units)
Table 137. Middle East & Africa Adenomyosis Drugs Sales by Application (2023-2028) & (K Units)
Table 138. Adenomyosis Drugs Raw Material
Table 139. Key Manufacturers of Adenomyosis Drugs Raw Materials
Table 140. Direct Channel Pros & Cons
Table 141. Indirect Channel Pros & Cons
Table 142. Adenomyosis Drugs Typical Distributors
Table 143. Adenomyosis Drugs Typical Customers
List of Figures
Figure 1. Adenomyosis Drugs Picture
Figure 2. Global Adenomyosis Drugs Revenue Market Share by Type in 2021
Figure 3. Hormone Medications
Figure 4. Anti-inflammatory Drugs
Figure 5. Others
Figure 6. Global Adenomyosis Drugs Revenue Market Share by Application in 2021
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Pharmacy
Figure 10. Others
Figure 11. Global Adenomyosis Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Adenomyosis Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Adenomyosis Drugs Sales (2017-2028) & (K Units)
Figure 14. Global Adenomyosis Drugs Price (2017-2028) & (US$/Unit)
Figure 15. Global Adenomyosis Drugs Production Capacity (2017-2028) & (K Units)
Figure 16. Global Adenomyosis Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Adenomyosis Drugs Market Drivers
Figure 18. Adenomyosis Drugs Market Restraints
Figure 19. Adenomyosis Drugs Market Trends
Figure 20. Global Adenomyosis Drugs Sales Market Share by Manufacturer in 2021
Figure 21. Global Adenomyosis Drugs Revenue Market Share by Manufacturer in 2021
Figure 22. Adenomyosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Adenomyosis Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Adenomyosis Drugs Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Adenomyosis Drugs Sales Market Share by Region (2017-2028)
Figure 26. Global Adenomyosis Drugs Revenue Market Share by Region (2017-2028)
Figure 27. North America Adenomyosis Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Europe Adenomyosis Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Adenomyosis Drugs Revenue (2017-2028) & (USD Million)
Figure 30. South America Adenomyosis Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Adenomyosis Drugs Revenue (2017-2028) & (USD Million)
Figure 32. Global Adenomyosis Drugs Sales Market Share by Type (2017-2028)
Figure 33. Global Adenomyosis Drugs Revenue Market Share by Type (2017-2028)
Figure 34. Global Adenomyosis Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 35. Global Adenomyosis Drugs Sales Market Share by Application (2017-2028)
Figure 36. Global Adenomyosis Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Global Adenomyosis Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 38. North America Adenomyosis Drugs Sales Market Share by Type (2017-2028)
Figure 39. North America Adenomyosis Drugs Sales Market Share by Application (2017-2028)
Figure 40. North America Adenomyosis Drugs Sales Market Share by Country (2017-2028)
Figure 41. North America Adenomyosis Drugs Revenue Market Share by Country (2017-2028)
Figure 42. United States Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Adenomyosis Drugs Sales Market Share by Type (2017-2028)
Figure 46. Europe Adenomyosis Drugs Sales Market Share by Application (2017-2028)
Figure 47. Europe Adenomyosis Drugs Sales Market Share by Country (2017-2028)
Figure 48. Europe Adenomyosis Drugs Revenue Market Share by Country (2017-2028)
Figure 49. Germany Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Adenomyosis Drugs Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Adenomyosis Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Adenomyosis Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Adenomyosis Drugs Revenue Market Share by Region (2017-2028)
Figure 58. China Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Adenomyosis Drugs Sales Market Share by Type (2017-2028)
Figure 65. South America Adenomyosis Drugs Sales Market Share by Application (2017-2028)
Figure 66. South America Adenomyosis Drugs Sales Market Share by Country (2017-2028)
Figure 67. South America Adenomyosis Drugs Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Adenomyosis Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Adenomyosis Drugs Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Adenomyosis Drugs Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Adenomyosis Drugs Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Adenomyosis Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Adenomyosis Drugs in 2021
Figure 79. Manufacturing Process Analysis of Adenomyosis Drugs
Figure 80. Adenomyosis Drugs Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のオシメルチニブ医薬品市場2022年：市場規模予測（～2028年）
  • 世界のエクセナチド薬物市場2022年：市場規模予測（～2028年）
  • 世界のペガスパルガーゼ薬物市場2022年：市場規模予測（～2028年）
  • 世界のリロナセプト薬物市場2022年：市場規模予測（～2028年）
  • 世界のブリナツモマブ治療薬市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19101 )"世界の腺筋症治療薬市場2022年：市場規模予測（～2028年）" (英文：Global Adenomyosis Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。